İKİNCİ BASAMAK DEVLET HASTANESİNDE İKİ FARKLI HELICOBACTER PYLORI TEDAVİ REJİMİNİN ETKİNLİĞİNİN DEĞERLENDİRİLMESİ.

Abstract

Objective: Helicobacter pylori (H. pylori) is a bacterium that infects more than half of the world's population and is defined as a class 1 carcinogen by the World Health Organization. The aim of this study is to compare the efficacy of treatments in patients with H. pylori positivity who were treated with a modified sequential treatment regimen containing levofloxacin or a bismuth-based quadruple treatment regimen in a secondary state hospital. Method: This study includes retrospective analysis of 167 patients who received and tolerated H. pylori eradication therapy between April 2021 and April 2022. The patients included in the study were divided into two groups according to the treatment regimen they received. Patients given a modified sequential treatment regimen containing levofloxacin (amoxicillin 1 g 2x1, pantoprazole 40 mg 2x1 for 7 days, followed by pantoprazole 40 mg 2x1 for 7 days, metronidazole 500 mg 3x1, levofloxacin 500 mg 1x1) Group 1 and the patients who were given bismuth-based quadruple therapy (14 days pantoprazole 40 mg 2x1, bismuth subsalicylate 262 mg 2x2, metronidazole 500 mg 3x1 and tetracycline 500 mg 4x1) were determined as Group 2. Results: A total of 14 patients (one in group 1 and 13 in group 2) could not tolerate H.pylori treatment, and eradication was achieved in 83 (90.2%) in group 1 and 70 (93.3%) in group 2 of 167 patients who completed the treatment. There was no statistically significant difference in eradication success rates in both treatment protocols (p=.470). There was no significant difference between the treatment groups in terms of age, gender, indications for endoscopy, endoscopic diagnoses, pathological findings, and eradication indications. Conclusion: Considering the eradication success rates found in our study, it supports that the modified sequential treatment regimen containing levofloxacin may be an alternative to bismuth-based treatment in the first-line treatment in our country, or a second-line treatment in patients who cannot tolerate bismuth-based treatment. However, further studies on modified sequential therapy containing levofloxacin are needed.